Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis
Announced top-line data for AMT-101 MARKET Phase 2 combination trial in patients with moderate-to-severe ulcerative colitis (UC)
Read more at globenewswire.comWe've received your inquiry. A specialist will reach out within 1 business day.
Start overAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis
Announced top-line data for AMT-101 MARKET Phase 2 combination trial in patients with moderate-to-severe ulcerative colitis (UC)
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| AMTI | 0.2630 | -0.0439 | -14.30% |
| Applied Molecular Transport Inc | |||